V. Bryan Lawlis - Apr 3, 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Apr 3, 2023
Transactions value $
-$248,880
Form type
4
Date filed
4/4/2023, 07:59 PM
Previous filing
Jun 9, 2022
Next filing
May 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $576K +8.5K +29.36% $67.81 37.5K Apr 3, 2023 Direct F1
transaction BMRN Common Stock Sale -$825K -8.5K -22.7% $97.09 29K Apr 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -8.5K -100% $0.00* 0 Apr 3, 2023 Common Stock 8.5K $67.81 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on August 29, 2022.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.